H. Lee Moffitt Cancer Center and Research Institute, Inc.

Brian Betts

Said M Sebti

Nicholas James Lawrence

Harshani Lawrence

Claudio Anasetti

Joseph Pidala

Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible T. In certain aspects, disclosed are compounds of Formula I-V.

Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease

Compositions and methods to reduce the risk of graft versus host disease (GVHD) in a subject receiving hematopoietic stem cell transplantation (HSCT). Also disclosed are methods for identifying patients receiving HSCT who are at risk for developing GVHD, methods for prognosing the severity of GVHD in a subject receiving HSCT, and methods for monitoring efficacy of a therapeutic for treatment of GVHD in a subject HSCT.

STAT3 phosphorylation during graft-versus-host disease

Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible T. In certain aspects, disclosed are compounds of Formula I-V. 

Growing community of inventors

Tampa, FL, United States of America

Brian Betts